Navigation Links
Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
Date:5/6/2010

RESEARCH TRIANGLE PARK, N.C., May 6 /PRNewswire-FirstCall/ --Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) today announced that Lawrence D. Stern, chairman and chief executive officer of Talecris, will present at the Bank of America Merrill Lynch 2010 Health Care Conference at 2:20 p.m., Thursday, May 13, 2010, at The Grand Hyatt in New York, N.Y.

A live webcast of Talecris' presentation will be accessible through the investor relations section of the Talecris Web site, www.talecris.com/investor-relations.htm. A replay of the webcast will be available until May 28, 2010, and can be accessed at the same Web address.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis.  For more information, please visit: www.talecris.com.


'/>"/>
SOURCE Talecris Biotherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
2. Siemens/Talecris Win Best Partnership in the Outsourcing Excellence Awards
3. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics
4. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
5. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
6. Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation
7. Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors
8. Oxford BioTherapeutics Appoints Michael Moore as Chairman
9. Oxygen Biotherapeutics, Inc. Expands Board of Directors
10. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
11. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Ky. and HOUSTON ... Inc. ("NX Prenatal") today announced the formation of ... together leading clinicians and industry veterans who enhance ... company as it accelerates development of its novel ... to provide medical, clinical and strategic guidance for ...
(Date:1/19/2017)... and Markets ... addition of the "Implantable Biomaterials Market Analysis & ... to their offering. Report Highlights: ... current and future market trends to identify the investment opportunities ... numbers Key market trends across the business segments, Regions ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... software to leading biopharmaceutical and medical device manufacturers and regulators, is proud to ... CFR Part 11-compliant email client designed to provide product vigilance departments with the ...
(Date:1/19/2017)... 2017  ArmaGen, Inc., today announced that it ... chief executive officer, as well as a member ... ArmaGen more than 17 years of executive management ... biotherapeutics and pharmaceuticals. "Mathias is ... and skillset necessary to lead ArmaGen to its ...
Breaking Biology Technology:
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
(Date:1/3/2017)... Jan. 3, 2017 Onitor, provider of digital ... Onitor Track, an innovative biometric data-driven program designed to ... month at the 2017 Consumer Electronics Show (CES) in ... In the U.S., the World Health Organization (WHO), have ... of adults who are overweight or obese. WHO also ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
Breaking Biology News(10 mins):